Vivimed Labs' Q2 FY 2025-26 Quarterly Results
- 18 Dec 2025
Result Summary
- Vivimed Labs Ltd reported a 4.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 16.0%.
- Its expenses for the quarter were up by 3.2% QoQ and down 6.0% YoY.
- The net profit increased 33.0% QoQ and increased 42.0% YoY.
- The earnings per share (EPS) of Vivimed Labs Ltd declined at 0.85 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 20.82 | 21.77 | 24.80 | -4.4% | -16.0% |
Total Expenses | 28.13 | 27.26 | 29.94 | 3.2% | -6.0% |
Profit Before Tax | -7.30 | -5.49 | -5.14 | 33.0% | 42.0% |
Tax | 0.00 | 0.00 | 0.00 | - | - |
Profit After Tax | -7.30 | -5.49 | -5.14 | 33.0% | 42.0% |
Earnings Per Share | -0.85 | -0.64 | -0.60 | 32.8% | 41.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Vivimed Labs Ltd is a pharmaceutical and chemical manufacturing company based in India. The company is involved in the production of active pharmaceutical ingredients (APIs), finished dosage formulations, and specialty chemicals. Vivimed Labs serves various industries, including healthcare and personal care, providing solutions that incorporate its expertise in chemical synthesis and pharmaceutical manufacturing. As of the latest available data, the company has faced challenges in its financial performance, as evidenced by the quarterly financial data presented. However, specific recent developments in the company's strategies or market positioning are not available within the scope of this report.
Revenue
During the second quarter of fiscal year 2026 (Q2FY26), Vivimed Labs Ltd recorded a total income of ₹20.82 crores. This represents a decline from the previous quarter (Q1FY26), where the total income was ₹21.77 crores, marking a quarter-over-quarter (QoQ) decrease of 4.4%. Compared to the same quarter in the previous fiscal year (Q2FY25), where total income was ₹24.80 crores, the year-over-year (YoY) decrease is 16.0%. These figures reflect a downward trend in revenue generation for the current quarter compared to both the preceding quarter and the same quarter in the previous year.
Profitability
For Q2FY26, Vivimed Labs Ltd reported a loss before tax of ₹7.30 crores. This is greater than the loss of ₹5.49 crores recorded in Q1FY26, indicating a 33.0% increase in losses quarter-over-quarter. Similarly, when compared to the loss of ₹5.14 crores in Q2FY25, there is a 42.0% increase in losses year-over-year. The company incurred a zero tax liability across these periods, resulting in a profit after tax mirroring the pre-tax loss figures. The earnings per share (EPS) for Q2FY26 was recorded at ₹-0.85, compared to ₹-0.64 in Q1FY26 and ₹-0.60 in Q2FY25, showing a significant increase in negative EPS of 32.8% QoQ and 41.7% YoY, respectively.
Operating Metrics
Total expenses for Vivimed Labs Ltd in Q2FY26 were ₹28.13 crores, which is an increase of 3.2% from ₹27.26 crores in Q1FY26. Compared to the previous year's corresponding quarter, where expenses were ₹29.94 crores, there is a YoY decrease of 6.0%. This indicates that while the company has managed to reduce its expenses year-over-year, the quarter-over-quarter increase in expenses has contributed to the overall loss for the quarter. The financial data provided does not include specific metrics such as P/E ratio, debt-to-equity ratio, or current ratio, and these cannot be calculated from the available data. However, the trends in income and expenses suggest areas where the company might focus its strategic efforts to manage its financial performance.